The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
If Gerard stopped selling for one minute we might have achieved the Board's aim. He needs to move on.
Hi shatter, I don't think the drop is OXB specific. The biotech industry as a whole has been sold off. I think it's a great long term hold. My only black swan event is what might come out of the recent court ruling for Pfizer to release its vaccine data much earlier. Let's hope everything is above board or anything vaccine related could get taken outside and shot.
Thanks Dracula1,
From my personal perspective I feel there is almost no momentum. The serenity surrounding the share price over the past c.6 months is almost unnerving given the 9 years of *****'s drawers I've experienced over the past c.10 years. A total calmness. Im in OXB, another Vulpes project which i recall Diggle remarking as much less startling than SCLP, and that has been a stunning return.... peak, trough, peak, trough, lower trough, bottom, Everest..... and this feels similar. I just hope our returns are somewhere close to where we all thought they might once have been (science aside, which I hope is life changing for us all).
GL everyone.
Chelsea 7, the day you stop contributing here I'll sell :) keep punching!
Thanks Ray, I didn't realise that was a done deal. I thought the holder had the option to convert if the loan wasn't repaid. Is the concern then that Redmile gets its big piece of the pie too early, before the true value has been reached? If the grievance is from an early II they perhaps should have put a lot more in a lot earlier.
Out of interest, how do we expect to repay it in 2 years, outside of refinancing?! I personally don't think it's Vulpes, given they have a seat firmly at the table.....I reckon they got the nod that votes were shorter than expected so stepped up. I'll dust off my 150k for good measure :)
Very true TF. Ignore history, dilution, current share price, etc. Today, everybody has a chance to buy into a 110 million market cap company with a staggering, funded pipeline. Look at the market caps of peers, especially in Redmiles' USA.